Drug Profile
Lidocaine transdermal patch - Immune Pharmaceuticals Inc
Alternative Names: ADL 87223; LidoPAIN BP; LidoPAIN HM; LidoPAIN SP; LidoPAIN TVLatest Information Update: 20 Jan 2022
Price :
$50
*
At a glance
- Originator EpiCept Corporation
- Developer EpiCept Corporation; Immune Pharmaceuticals Inc
- Class Acetanilides; Class Ib antiarrhythmics; Local anaesthetics; Non-opioid analgesics; Small molecules
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Back pain
- Discontinued Headache; Postoperative pain; Tinnitus
Most Recent Events
- 19 Jan 2018 No recent reports on development identified - Phase-II for Back pain in USA (Transdermal)
- 31 Dec 2017 Immune Pharmaceuticals has patent protection for lidocaine transdermal patch in USA and Mexico
- 31 Dec 2017 Immune Pharmaceuticals has patent pending for lidocaine transdermal patch in Mexico